Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease and Transplantation, Liver Disease Diagnosis and Treatment, Drug-Induced Hepatotoxicity and Protection, and Organ Transplantation Techniques and Outcomes.
Simvastatin and Rifaximin in Decompensated Cirrhosis
Prospective multicentre randomised controlled trial to assess the clinical effectiveness of the novel CirrhoCare digital therapeutic management system: a study protocol
Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis
Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
Mechanisms and treatment approaches for <scp>ACLF</scp>
The Use of Rifaximin in Patients With Cirrhosis
Management of the major complications of cirrhosis: Beyond guidelines
The role of RIPK1 mediated cell death in acute on chronic liver failure
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis
Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure
A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shirota in Stable Cirrhotic Patients
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF
Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial
Statins: Old drugs as new therapy for liver diseases?
Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity
Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure
Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013
A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis
The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure